Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Invitae Corporation is a diagnostics & research business based in the US. Invitae Corporation shares (NVTA) are listed on the NYSE and all prices are listed in US Dollars. Invitae Corporation employs 2,600 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$28.58|
|52-week range||$24.16 - $61.59|
|50-day moving average||$29.27|
|200-day moving average||$30.63|
|Wall St. target price||$40.44|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.76|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||3.93%|
|1 month (2021-09-22)||-9.93%|
|3 months (2021-07-22)||0.63%|
|6 months (2021-04-22)||-20.52%|
|1 year (2020-10-21)||-35.10%|
|2 years (2019-10-21)||61.10%|
|3 years (2018-10-19)||122.24%|
|5 years (2016-10-21)||274.08%|
|Revenue TTM||$389.1 million|
|Gross profit TTM||$81.3 million|
|Return on assets TTM||-11.94%|
|Return on equity TTM||-20.07%|
|Market capitalisation||$6 billion|
TTM: trailing 12 months
There are currently 26.6 million Invitae Corporation shares held short by investors – that's known as Invitae Corporation's "short interest". This figure is 0% down from 26.6 million last month.
There are a few different ways that this level of interest in shorting Invitae Corporation shares can be evaluated.
Invitae Corporation's "short interest ratio" (SIR) is the quantity of Invitae Corporation shares currently shorted divided by the average quantity of Invitae Corporation shares traded daily (recently around 3.0 million). Invitae Corporation's SIR currently stands at 9. In other words for every 100,000 Invitae Corporation shares traded daily on the market, roughly 9000 shares are currently held short.
However Invitae Corporation's short interest can also be evaluated against the total number of Invitae Corporation shares, or, against the total number of tradable Invitae Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Invitae Corporation's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Invitae Corporation shares in existence, roughly 120 shares are currently held short) or 0.1305% of the tradable shares (for every 100,000 tradable Invitae Corporation shares, roughly 131 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Invitae Corporation.
Find out more about how you can short Invitae Corporation stock.
We're not expecting Invitae Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Invitae Corporation's shares have ranged in value from as little as $24.16 up to $61.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Invitae Corporation's is 1.8307. This would suggest that Invitae Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. It has a collaboration with Pacific Biosciences of California, Inc. to develop a production-scale high-throughput HiFi sequencing platform. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.